Mesothelioma affects mostly older individuals who have been occupationally exposed to
asbestos. The global mesothelioma incidence and mortality rates are unknown, because …

Abstract A new World Health Organization (WHO) Classification of Tumors of the Pleura has
recently been published. While the histologic classification of pleural malignant …

The distinction between malignant mesothelioma and reactive mesothelial proliferation can
be challenging both on histology and cytology. Recently, variants of the BRCA1-associated …

Introduction Molecular and immunologic breakthroughs are transforming the management of
thoracic cancer, although advances have not been as marked for malignant pleural …

Immunohistochemistry plays an indispensable role in accurate diagnosis of malignant
mesothelioma, particularly in morphologically challenging cases and in biopsy and cytology …

Objectives Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial
hyperplasia (RMH) is still challenging. Detection of homozygous deletion (HD) of 9p21 …

Ancillary studies facilitate accurate diagnosis of morphologically challenging mesothelial
proliferations. The current diagnostic algorithm proceeds from BAP1 immunohistochemistry …

Mesothelial tumors are classified into benign or preinvasive tumors, and mesotheliomas.
The benign or preinvasive group includes adenomatoid tumors, well-differentiated papillary …

The 2015 WHO classification of pleural mesotheliomas includes three major histologic
subtypes—epithelioid, sarcomatoid, and biphasic. Recent genomic data has supported the …

The separation of benign from malignant mesothelial proliferations is crucial to patient care
but is frequently morphologically difficult. Context.—To briefly review adjunctive tests …